The American Journal of Managed Care

Determining the Impact of Demodex Blepharitis on Patients

AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...
The American Journal of Managed Care

Exploring Demodex Blepharitis From a Clinical Perspective

AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...
Monthly Prescribing Reference

Xdemvy Approved for Treatment of Demodex Blepharitis

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...
Business Insider

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...
Healio

‘Mite Party’ campaign designed to educate consumers about Demodex blepharitis

Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...
MedPage Today

First Treatment for Demodex Blepharitis Wins FDA Approval

The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex mites, ...
MM&M

Tarsus Pharmaceuticals throws a Mite Party to combat demodex blepharitis

Welcome to the Mite Party. In its latest effort to raise awareness about demodex blepharitis, an eye condition that affects 25 million Americans, Tarsus Pharmaceuticals is throwing a party — a Mite ...
Star-Gazette

FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Allure on MSN

Irritated Eyes? You Might Have Mites in Them

In better news: They're totally treatable and actually pretty common (especially for makeup wearers).
Seeking Alpha

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...
Nasdaq

Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven ...